NEW YORK (GenomeWeb News) — Investment bank Cowen & Co. today downgraded shares of Illumina to "Neutral" from "Outperform."
 
Reuters today reported that Cowen said the shares "appear reasonably valued, noting the firm's shares were up 154 percent year-to-date."
 
Reuters reported that the brokerage said "many investors agree with its view that Illumina's high-throughput genotyping technology is best in class."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.